Project Grant HT94252410114
Award Date
4/15/24
Completion Date
4/14/27
Dollars Obligated
$925K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
This federal Project Grant award of $1,000,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at Brigham & Women's Hospital to develop precision nonviral brain delivery of CD33 targeting siRNA for the treatment of Alzheimer's disease. The research aims to characterize novel nanoparticles that can efficiently deliver CD33 siRNAs to microglia in the brain, evaluate microglial uptake, and assess the therapeutic efficacy on...
Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
Brigham & Women's Hospital Inc. was awarded a $1,859,665 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research to advance understanding of how...
Brigham & Women's Hospital Inc. was awarded an $895,001 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award will support in vitro studies targeting proinflammatory mediators to restore regulatory T cell homeostatic expansion and function in amyotrophic lateral sclerosis. The research aims to develop surrogates for in vivo applications in investigating medical solutions for the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,858,368.00 to Brigham & Women's Hospital Inc. to support research on the role of the SORL1-retromer biology in the pathogenesis of Alzheimer's disease. The award has an initial term from September 30, 2024 to August 31, 2027. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution in Boston, Massachusetts, affiliated with Harvard Medical...
This $691,213 Project Grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports research into bioengineered 3D human brain systems to investigate risk factors, mechanisms, and treatments for traumatic brain injury-induced Alzheimer's disease. Tufts University is the primary awardee and will conduct research. Massachusetts General Hospital will provide $691,213 in research services as a sub-awardee. The overarching...
The Defense Health Agency awarded a $864,498 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc. for a project titled "TARGETING NEUROINFLAMMATION TO PROMOTE NEUROLOGICAL RECOVERY AFTER TRAUMATIC SPINAL CORD INJURY". The project period runs from August 1, 2025 to July 31, 2028. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution affiliated with Harvard Medical...